Melinda McClellan, APRN
Family · Barberton, OHNPI 1457722365
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (57.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. AbbVie accounts for 72.6% of it on its own, with 24 other manufacturers making up the rest. Among family clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 572 payments — averaging $44.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$18K
- Inspire Medical Systems, Inc.$2K
- Teva Pharmaceuticals USA, Inc.$1K
- Pfizer$525
- Jazz Pharmaceuticals Inc.$469
- Biogen$463
- plus $3K from 19 others
What the payments were for
- Consulting fees$1501%
- Speaking & faculty fees$14,51357%
- Travel & lodging$1,0424%
- Food & beverage$9,42737%
- Education$2891%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 255 | $18,446 |
| Inspire Medical Systems, Inc. | 15 | $1,749 |
| Teva Pharmaceuticals USA, Inc. | 106 | $1,246 |
| Pfizer | 37 | $525 |
| Jazz Pharmaceuticals Inc. | 19 | $469 |
| Biogen | 15 | $463 |
| SK Life Science, Inc. | 9 | $439 |
| Lilly USA, LLC | 24 | $420 |
| Eisai Inc. | 12 | $295 |
| Biohaven Pharmaceuticals, Inc. | 20 | $195 |
| Lundbeck LLC | 6 | $178 |
| AstraZeneca(2 entities) | 8 | $152 |
| Biohaven Pharmaceutical Holding Company Ltd. | 12 | $151 |
| Axsome Therapeutics, Inc. | 8 | $142 |
| Otsuka America Pharmaceutical, Inc. | 5 | $113 |
| Genentech USA, Inc. | 7 | $108 |
| Harmony Biosciences LLC | 2 | $93 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $76 |
| UCB, Inc. | 2 | $49 |
| Novartis | 2 | $25 |
| Upsher-smith Laboratories LLC | 1 | $23 |
| ZOLL Respicardia, Inc. | 1 | $21 |
| Neurelis, Inc. | 1 | $18 |
| Impel Pharmaceuticals LLC | 1 | $14 |
| Amgen | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$25,421 in reported general payments places this provider in the 95th percentile of 6,812 family providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 310 | $389,886 |
| UbrelvyUbrogepant | 167 | $182,066 |
| QuliptaAtogepant | 144 | $161,985 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 48 | $73,423 |
| Emgality PenGalcanezumab-Gnlm | 69 | $65,730 |
| Aimovig AutoinjectorErenumab-Aooe | 73 | $63,477 |
| BotoxOnabotulinumtoxina | 45 | $55,503 |
| VyeptiEptinezumab-Jjmr | 18 | $55,502 |
| ReyvowLasmiditan Succinate | 43 | $34,078 |
| NeuproRotigotine | 18 | $28,150 |
| FycompaPerampanel | 13 | $14,752 |
| BelsomraSuvorexant | 20 | $8,480 |
| Levetiracetam | 131 | $2,455 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 66 | $2,427 |
| Carbamazepine | 26 | $2,234 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta, Botox | $18,446 | $399,554356 claims |
| PfizerNurtec Odt | $525 | $389,886310 claims |
| Lundbeck LLCVyepti | $178 | $55,50218 claims |
| Lilly USA, LLCReyvow | $420 | $34,07843 claims |
| UCB, Inc.Neupro | $49 | $28,15018 claims |
| Eisai Inc.Fycompa | $295 | $14,75213 claims |
| Upsher-smith Laboratories LLCTopiramate | $23 | $60267 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,812 family providers in Ohio.
Other family in Barberton
- Leigh Ann PanschDayton$670K
- Natalie BelliniMayfield Heights$582K
- Kaitlyn LovettMontgomery$286K
- Amy RossDayton$281K
- Renee OttSandusky$179K
- Megan MillerSpringfield$156K
- George KnightCincinnati$130K
- Jillian HuntCincinnati$116K
- Florence StewartNew Albany$113K
- Kirt MunsonToledo$108K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.